The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 935-940

  Moul, Judd W ^a   Connelly, Roger R ^b   Perahia, Barak ^b   Mcleod, David G ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

Acid phosphatase; Prognosis; Prostate

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

EID: 0031908340     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63775-3     Document Type: Article

References (31)

1. Smith, O. S., Catalona, W. J. and Herschman, J. D.: Longitudinal screening for prostate cancer with prostate-specific antigen. J.A.M.A., 276: 1309, 1996.
2. Parker, S. I., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics 1996. CA, 46: 5, 1996.
3. Lu-Yao, G. L., McLerran, D., Wasson, J. H. and Wennberg, J. E.: An assessment of radical prostatectomy:time trends, geographic variation and outcomes. J.A.M.A., 269: 2633, 1993.
4. Lu-Yao, G. L., Potoshy, A. L., Albertsen, P. C., Wasson, J. H., Barry, M. J. and Wennberg, J. E.: Follow-up prostate cancer treatments after radical prostatectomy: a population based study. J. Nat. Cancer Inst., 88: 16, 1996.
5. Partin, A. W., Piantadosea, S., Sandra, M. G., Epstein, J. I., Marshall, F. F. and Mohler, J. L.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995.
6. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J. Urol., 156: 1511, 1996.
7. Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G. and Moul, J. W.: Ki-67 expression is an independent prognostic marker of recurrence in patients with organ confined prostate cancer after radical prostatectomy. J. Urol., 156: 1064, 1996.
8. Moreno, J. G., Croce, C. M., Fischer, R., Monne, M., Vihko, S., Mulholland, S. G. and Gomella, L. G.: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res., 52: 6110, 1992.
9. Katz, A. E., Olsson, C. A., Raffo, A. J., Cama, C., Perlman, H., Seaman, E., O'Toole, K. M., McMahon, D., Benson, M. C. and Buttyan, R.: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 43: 765, 1994.
10. Israeli, R. S., Miller, W. H., Jr., Su, S. L., Powell, C. T., Fair, W. R., Samadi, D. S., Huryk, R. F., DeBalsio, A., Edwards, E. T. and Wise, G. J.: Sensitive nested reverse transcription chain reaction detection of circulating prostatic tumor cells: comparison to prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res., 54: 6306, 1994.
11. Wood, D. P., Jr., Banks, E. R., Humphreys, S., McRoberts, J. W. and Rangnekar, V. M.: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer, 74: 2533, 1994.
12. Arfman, E. W., Vessella, R. L., Stray, J. E. and Lange, P. H.: Reverse transcriptase polymerase chain reaction (RT-PCR) detection of circulating prostate cancer cells - a methodological and early clinical trial evaluation with primers for PSA and PSM. J. Urol., part 2, 153: 294A, abstract 261, 1995.
13. Seiden, M. V., Kantoff, P. W., Krithivas, K., Propert, K., Bryant, M., Haltom, E., Gaynes, L., Kaplan, I., Bubley, G. and DeWolf, W.: Detection of circulating tumor cells in men with localized prostate cancer. J. Clin. Oncol., 12: 2634, 1994.
14. Jaakkola, S., Vornanen, T., Leinonen, J., Rannikko, S. and Stenman, U.: Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate specific antigen. Clin. Chem., 41: 182, 1995.
15. Ghossein, R., Scher, H., Gerald, W., Kelly, W. K., Curley, T., Amsterdam, A., Zhang, Z. and Rosai, J.: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol., 13: 1195, 1995.
16. Sokoloff, M. H., Tso, C., Kaboo, R., Nelson, S., Ko, J., Dorey, F., Figlin, R. A., Pang, S., deKernion, J. and Belldegrun, A.: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J. Urol., 156: 1560, 1996.
17. Gutman, E. B., Sproul, E. E. and Gutman, A. B.: Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Amer. J. Cancer, 28: 485, 1936.
18. Gutman, A. B. and Gutman, E. B.: "Acid" phosphatase occurring in serum of patients with metastasizing carcinoma of prostate gland. J. Clin. Invest., 17: 473, 1938.
19. Lowe, F. C. and Trauzzi, S. J.: Prostate acid phosphatase in 1993: its limited clinical value. Urol. Clin. N. Amer., 20: 589, 1993.
20. Burnett, A. L., Chan, D. W., Brendler, C. B. and Walsh, P. C.: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J. Urol., 148: 1832, 1992.
21. Roy, A. V., Brower, M. E. and Hayden, J. E.: Sodium thymoph-thalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin. Chem., 17: 1093, 1971.
22. Whitesel, J. A., Donohue, R. E., Mani, J. H., Mohr, S., Scanavino, D. J., Augspurger, R. R., Biber, R. J., Fauver, H. E., Wettlaufer, J. N. and Pfister, R. R.: Acid phosphatase: its influence on the management of carcinoma of the prostate. J. Urol., 131: 70, 1984.
23. Gleason, D. F. and the Veterans Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostate carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea and Febiger, pp. 171-197, 1977.
24. Mostofi, F. K., Sesterhenn, I. A. and Sobin, L. H.: International Histologic Classification of Tumors No. 22: Histological Typing of Prostate Tumors. New York: Waverly, 1980.
25. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer, 73: 104, 1994.
26. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostatic specific antigen: update. J. Urol, 152: 1358, 1994.
27. Bahnson, R. R. and Catalona, W. J.: Adverse implications of acid phosphatase levels in the upper range of normal. J. Urol., 137: 427, 1987.
28. Salo, J. O. and Rannikko, S.: The value of acid phosphatase measurements in predicting extra prostatic cancer growth before radical prostatectomy. Brit. J. Urol., 62: 439, 1988.
29. Paulson, D. F., Moul, J. W. and Walther, P. J.: Radical prostatectomy in clinical stages T1-2 N0M0 prostatic adenocarcinoma: long-term results. J. Urol., 144: 1180, 1990.
30. Katz, A. E., deVries, G. M. and Begg, M. D.: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer, 75: 1642, 1995.
31. Gao, C., McLeod, D. G., Maheswari, S., Srivastava, S. and Moul, J. W.: Evaluation of reverse transcriptase polymerase chain reaction (RT-PCR) prostate specific antigen assay for molecular staging of prostate cancer. Proc. Amer. Assn. Cancer Res. 38: 268, 1997.